Early pre-clinical studies utilised AZD1480, a JAK1/2 inhibitor, and demonstrated STAT3 inhibition and anti-tumour activity in HPV- HNSCC PDX models [231]. The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.